 Mark Gregory
Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| fms-Like Tyrosine Kinase 3 | 4 | 2022 | 42 | 1.360 |
Why?
| | Proto-Oncogene Proteins c-myc | 7 | 2012 | 115 | 1.020 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2022 | 532 | 0.900 |
Why?
| | Glutamine | 2 | 2019 | 88 | 0.820 |
Why?
| | Benzothiazoles | 2 | 2017 | 37 | 0.770 |
Why?
| | Phenylurea Compounds | 2 | 2017 | 85 | 0.730 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2022 | 671 | 0.680 |
Why?
| | Oxidation-Reduction | 2 | 2019 | 940 | 0.660 |
Why?
| | Benzeneacetamides | 1 | 2017 | 7 | 0.630 |
Why?
| | Glutaminase | 1 | 2017 | 9 | 0.630 |
Why?
| | Thiadiazoles | 1 | 2017 | 21 | 0.620 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2014 | 93 | 0.600 |
Why?
| | Leukemia | 1 | 2019 | 208 | 0.580 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 62 | 0.580 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 41 | 0.570 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 49 | 0.570 |
Why?
| | Fusion Proteins, bcr-abl | 3 | 2014 | 61 | 0.520 |
Why?
| | Antineoplastic Agents | 4 | 2023 | 1974 | 0.500 |
Why?
| | Energy Metabolism | 1 | 2019 | 767 | 0.470 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2019 | 740 | 0.410 |
Why?
| | Cell Line, Tumor | 9 | 2022 | 2851 | 0.400 |
Why?
| | Philadelphia Chromosome | 1 | 2010 | 15 | 0.380 |
Why?
| | Protein Kinase Inhibitors | 6 | 2022 | 811 | 0.370 |
Why?
| | NFATC Transcription Factors | 1 | 2010 | 82 | 0.360 |
Why?
| | Wnt Proteins | 1 | 2010 | 140 | 0.350 |
Why?
| | Glycogen Synthase Kinase 3 | 2 | 2012 | 83 | 0.340 |
Why?
| | Tumor Suppressor Protein p14ARF | 2 | 2005 | 6 | 0.330 |
Why?
| | Cell Proliferation | 4 | 2019 | 2275 | 0.330 |
Why?
| | Apoptosis | 10 | 2022 | 2484 | 0.310 |
Why?
| | Mice, Inbred NOD | 3 | 2017 | 574 | 0.290 |
Why?
| | Calcium | 2 | 2013 | 1169 | 0.260 |
Why?
| | Cell Survival | 3 | 2019 | 1047 | 0.260 |
Why?
| | RNA, Small Interfering | 4 | 2016 | 564 | 0.250 |
Why?
| | Mice | 12 | 2019 | 15520 | 0.240 |
Why?
| | Ubiquitins | 2 | 2000 | 34 | 0.230 |
Why?
| | Multienzyme Complexes | 2 | 2000 | 64 | 0.230 |
Why?
| | Cysteine Endopeptidases | 2 | 2000 | 61 | 0.230 |
Why?
| | Cyclosporine | 3 | 2014 | 173 | 0.230 |
Why?
| | Cell Nucleus | 2 | 2003 | 580 | 0.220 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2025 | 0.220 |
Why?
| | Burkitt Lymphoma | 2 | 2000 | 53 | 0.220 |
Why?
| | Peptide Hydrolases | 1 | 2003 | 108 | 0.220 |
Why?
| | Genes, myc | 2 | 2012 | 46 | 0.220 |
Why?
| | Animals | 15 | 2019 | 33381 | 0.210 |
Why?
| | Epididymis | 1 | 2000 | 9 | 0.190 |
Why?
| | Hormones | 1 | 2000 | 135 | 0.180 |
Why?
| | Cell Division | 2 | 2004 | 776 | 0.180 |
Why?
| | Head and Neck Neoplasms | 1 | 2023 | 471 | 0.160 |
Why?
| | Phosphorylation | 6 | 2022 | 1633 | 0.160 |
Why?
| | Hydrazines | 1 | 2016 | 31 | 0.150 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 576 | 0.140 |
Why?
| | Transfection | 4 | 2004 | 888 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 1390 | 0.140 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 356 | 0.140 |
Why?
| | Signal Transduction | 5 | 2016 | 4709 | 0.140 |
Why?
| | Glutamic Acid | 1 | 2017 | 224 | 0.140 |
Why?
| | Oligomycins | 1 | 2014 | 8 | 0.130 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 18 | 0.130 |
Why?
| | Imatinib Mesylate | 2 | 2014 | 64 | 0.130 |
Why?
| | Threonine | 2 | 2012 | 45 | 0.130 |
Why?
| | RNA Interference | 2 | 2014 | 460 | 0.120 |
Why?
| | Dasatinib | 2 | 2014 | 46 | 0.120 |
Why?
| | Tumor Cells, Cultured | 2 | 2010 | 874 | 0.120 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 61 | 0.120 |
Why?
| | Thiazoles | 2 | 2014 | 121 | 0.120 |
Why?
| | Flow Cytometry | 3 | 2014 | 1085 | 0.120 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 965 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 226 | 0.110 |
Why?
| | Survival Analysis | 1 | 2016 | 1267 | 0.110 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2012 | 58 | 0.110 |
Why?
| | Humans | 17 | 2023 | 118974 | 0.110 |
Why?
| | Benzimidazoles | 1 | 2013 | 140 | 0.110 |
Why?
| | Gene Expression Regulation | 2 | 2004 | 2445 | 0.100 |
Why?
| | Disease Models, Animal | 2 | 2019 | 3730 | 0.100 |
Why?
| | Hematologic Neoplasms | 1 | 2013 | 133 | 0.100 |
Why?
| | Pyrimidines | 2 | 2014 | 382 | 0.100 |
Why?
| | Cell Line | 4 | 2005 | 2707 | 0.100 |
Why?
| | Blotting, Western | 2 | 2012 | 1194 | 0.100 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2005 | 455 | 0.100 |
Why?
| | Amino Acid Substitution | 3 | 2012 | 276 | 0.090 |
Why?
| | COS Cells | 2 | 2000 | 184 | 0.090 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2012 | 317 | 0.090 |
Why?
| | Tumor Microenvironment | 2 | 2023 | 454 | 0.090 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2000 | 139 | 0.090 |
Why?
| | Benzamides | 1 | 2010 | 176 | 0.090 |
Why?
| | Mitosis | 2 | 2000 | 172 | 0.090 |
Why?
| | Neoplasm Proteins | 2 | 2004 | 401 | 0.090 |
Why?
| | Mice, Inbred C57BL | 3 | 2014 | 4908 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 982 | 0.080 |
Why?
| | Piperazines | 1 | 2010 | 316 | 0.080 |
Why?
| | Female | 6 | 2017 | 61565 | 0.080 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 628 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2010 | 681 | 0.070 |
Why?
| | Binding Sites | 2 | 2004 | 1224 | 0.060 |
Why?
| | Ubiquitin | 1 | 2003 | 66 | 0.060 |
Why?
| | Enzyme Inhibitors | 2 | 2023 | 827 | 0.060 |
Why?
| | Transcriptional Activation | 1 | 2005 | 348 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2004 | 298 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2010 | 2657 | 0.050 |
Why?
| | Everolimus | 1 | 2022 | 64 | 0.050 |
Why?
| | Cytokines | 1 | 2010 | 1900 | 0.050 |
Why?
| | Mutation | 3 | 2022 | 3457 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2022 | 156 | 0.050 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2005 | 1167 | 0.050 |
Why?
| | Protein Binding | 2 | 2004 | 1975 | 0.050 |
Why?
| | Growth Inhibitors | 1 | 2000 | 43 | 0.050 |
Why?
| | Adrenal Glands | 1 | 2000 | 72 | 0.050 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2000 | 50 | 0.050 |
Why?
| | DNA, Complementary | 1 | 2000 | 268 | 0.050 |
Why?
| | 3T3 Cells | 1 | 2000 | 141 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2004 | 2071 | 0.050 |
Why?
| | Organ Specificity | 1 | 2000 | 278 | 0.050 |
Why?
| | Mammary Glands, Animal | 1 | 2000 | 124 | 0.050 |
Why?
| | Pituitary Gland | 1 | 2000 | 163 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 369 | 0.040 |
Why?
| | Sequence Deletion | 1 | 2000 | 171 | 0.040 |
Why?
| | Prostate | 1 | 2000 | 158 | 0.040 |
Why?
| | Tubulin | 1 | 2000 | 122 | 0.040 |
Why?
| | Uterus | 1 | 2000 | 194 | 0.040 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2012 | 21 | 0.040 |
Why?
| | Molecular Sequence Data | 2 | 2004 | 2871 | 0.040 |
Why?
| | CHO Cells | 2 | 2012 | 143 | 0.040 |
Why?
| | Ovary | 1 | 2000 | 205 | 0.040 |
Why?
| | Middle Aged | 2 | 2016 | 27617 | 0.040 |
Why?
| | Cricetinae | 2 | 2012 | 262 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2000 | 408 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 653 | 0.040 |
Why?
| | Protein Structure, Tertiary | 2 | 2012 | 823 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2000 | 551 | 0.040 |
Why?
| | Rats | 2 | 2004 | 5392 | 0.030 |
Why?
| | Fibroblasts | 1 | 2000 | 842 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 56 | 0.030 |
Why?
| | Precipitin Tests | 2 | 2004 | 93 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 221 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 339 | 0.030 |
Why?
| | S-Phase Kinase-Associated Proteins | 1 | 2012 | 18 | 0.030 |
Why?
| | Transcription, Genetic | 2 | 2012 | 1323 | 0.030 |
Why?
| | Early Growth Response Protein 1 | 1 | 2012 | 31 | 0.030 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2013 | 71 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 226 | 0.030 |
Why?
| | Ubiquitination | 1 | 2012 | 87 | 0.030 |
Why?
| | Binding, Competitive | 1 | 2012 | 205 | 0.030 |
Why?
| | Vinblastine | 1 | 2012 | 68 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2012 | 105 | 0.030 |
Why?
| | Cytarabine | 1 | 2012 | 53 | 0.030 |
Why?
| | Peptide Mapping | 2 | 2004 | 63 | 0.030 |
Why?
| | ras Proteins | 1 | 2013 | 141 | 0.030 |
Why?
| | Etoposide | 1 | 2012 | 149 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 237 | 0.030 |
Why?
| | Protein Stability | 1 | 2012 | 164 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2012 | 363 | 0.030 |
Why?
| | Wnt Signaling Pathway | 1 | 2013 | 150 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2013 | 219 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2014 | 407 | 0.020 |
Why?
| | Cisplatin | 1 | 2012 | 271 | 0.020 |
Why?
| | HeLa Cells | 1 | 2012 | 583 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 618 | 0.020 |
Why?
| | Mitochondria | 1 | 2014 | 786 | 0.020 |
Why?
| | Brain | 1 | 2000 | 2490 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 2680 | 0.020 |
Why?
| | Genomics | 1 | 2013 | 706 | 0.020 |
Why?
| | Okadaic Acid | 1 | 2004 | 12 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2012 | 4077 | 0.020 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2004 | 155 | 0.020 |
Why?
| | Carcinogens | 1 | 2004 | 108 | 0.010 |
Why?
| | Paclitaxel | 1 | 2004 | 195 | 0.010 |
Why?
| | Dogs | 1 | 2004 | 371 | 0.010 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 180 | 0.010 |
Why?
| | Gene Deletion | 1 | 2004 | 361 | 0.010 |
Why?
| | Protein Kinase C | 1 | 2004 | 297 | 0.010 |
Why?
| | MAP Kinase Signaling System | 1 | 2004 | 292 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 828 | 0.010 |
Why?
| | Male | 2 | 2014 | 57801 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 550 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2014 | 9342 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 1945 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2000 | 308 | 0.010 |
Why?
| | Microtubules | 1 | 2000 | 241 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 6412 | 0.010 |
Why?
| | Adult | 1 | 2014 | 31512 | 0.010 |
Why?
|
|
Gregory's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|